Julie Grisham, MS

Freelance Science Writer

Recent Blog Posts

Pictured: ESK1 Monoclonal Antibody
In the Lab
Wednesday, March 13, 2013

Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

Pictured: Massage Therapy
In the Clinic
Monday, March 4, 2013

Peripheral neuropathy — a nerve disorder that can cause weakness, numbness, tingling, and pain — is a common chemotherapy side effect. Treatments are available to help improve your quality of life.

Pictured: Major Trends in Modern Cancer Research Seminar
Video
Friday, March 1, 2013

At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.

Pictured: Prasad Adusumilli
In the Lab
Thursday, January 3, 2013

A team from Memorial Sloan Kettering has found that the makeup of immune cells in a lung tumor and in tissue surrounding a tumor can predict whether the cancer will recur after surgery.

Pictured: Tim Ahles
Q&A
Thursday, December 27, 2012

Problems with cognitive function can significantly impact a person’s quality of life after cancer treatment. New research is focused on the link between cancer treatment and cognitive changes.

Pictured: Michel Sadelain
In the Lab
Tuesday, December 18, 2012

Memorial Sloan Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.

In the News
Friday, November 16, 2012

Memorial Sloan Kettering has been praised for taking a stand on the price for a new cancer drug that costs more than twice as much as another, similar drug.

Pictured: Ping Chi
Q&A
Friday, November 2, 2012

Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.

Pictured: Structure of Synthesized Erythropoietin
In the Lab
Monday, October 8, 2012

Researchers have produced a fully synthetic, functional version of erythropoietin, the hormone that controls production of red blood cells.

Pictured: Richard Barakat
Honor
Monday, October 1, 2012

Dr. Barakat will serve as president of two prestigious societies for gynecologic cancer, allowing him to influence how women with these cancers are cared for both in the United States and around the world.

Pictured: Alexander Rudensky
Announcement
Wednesday, September 26, 2012

Dr. Rudensky studies the development of white blood cells called T lymphocytes, which participate in the immune system response to infection. He joined the Sloan Kettering Institute in 2009.

Feature
Friday, September 21, 2012

With the genomics revolution, scientists and physicians have increasingly been able to peer at the inner workings of tumor cells and pinpoint the specific genetic changes that transform them from their cells of origin into cancer.

Pictured: Joao Xavier and Eric Pamer
In the Clinic
Thursday, July 19, 2012

New studies investigate how the use of antibiotics affects the balance of both harmful and beneficial bacteria in patients undergoing stem cell transplantation.

Pictured: Isabelle Rivière and Michel Sadelain
In the Clinic
Monday, July 16, 2012

Memorial Sloan Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

Pictured: Joan Massagué
In the Lab
Friday, July 6, 2012

A team of investigators from Memorial Sloan Kettering has shown for the first time that tumor growth, metastasis, and chemotherapy resistance are connected to the same molecular changes inside breast cancer cells.